ICU Medical COO sells 8,929 shares at $182.93

ICU Medical Inc. (ICUI) Chief Operating Officer Christian B. Voigtlander reported an open-market sale of 8,929 shares of common stock on 2026-08-11 at a weighted average price of $182.93 per share, with individual trade prices ranging from $182.85 to $183.03.

Rhea-AI Filing Summary

ICU Medical Inc. (ICUI) Chief Operating Officer Christian B. Voigtlander reported an open-market sale of 8,929 shares of common stock on 2026-08-11 at a weighted average price of $182.93 per share, with individual trade prices ranging from $182.85 to $183.03. Following this transaction, he directly owns 37,377 shares of ICU Medical common stock.

Insider Trade Summary

Net Seller: 8,929 shares

Net Sell 1 txn

Insider Voigtlander Christian B.

Role Chief Operating Officer

Sold 8,929 shs ($1.63M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	8,929	$182.9325	$1.63M

Holdings After Transaction: Common Stock — 37,377 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $182.85 to $183.03, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Key Figures

Shares sold: 8,929 shares Weighted average sale price: $182.9325 per share Shares owned after sale: 37,377 shares

3 metrics

Shares sold 8,929 shares Non-derivative open-market sale on 2026-08-11

Weighted average sale price $182.9325 per share Common stock sale, prices from $182.85 to $183.03

Shares owned after sale 37,377 shares Direct ownership of common stock following transaction

Key Terms

weighted average price, open market, non-derivative

3 terms

weighted average price financial

"The price reported ... is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market financial

"transaction code description: Sale in open market or private transaction"

An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.

non-derivative financial

"transaction_type" : "non-derivative""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ICUI’s COO report on this Form 4?

ICU Medical’s COO Christian B. Voigtlander reported a sale of 8,929 common shares on 2026-08-11. The sale was an open-market transaction at a weighted average price of $182.93 per share.

At what price did the ICUI shares sell in the COO’s August 11 trade?

The ICUI shares sold at a weighted average price of $182.93. Individual trades occurred in multiple transactions at prices ranging from $182.85 to $183.03 per share, according to the filing footnote.

How many ICUI shares does the COO hold after this reported sale?

After the reported sale, the COO directly holds 37,377 shares of ICU Medical common stock. This figure reflects his post-transaction ownership as stated in the Form 4’s non-derivative holdings column.

How many ICUI shares did the COO sell in this Form 4 transaction?

The COO sold 8,929 shares of ICU Medical common stock. The transaction is classified as a non-derivative open-market sale with the acquired/disposed code "D" for disposition in the Form 4 data.

Was the ICUI COO’s August 11 share sale under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative. There is no footnote indicating that this 8,929-share sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan.

What type of security was involved in the ICUI COO’s transaction?

The transaction involved ICU Medical common stock as a non-derivative security. The Form 4 lists a single open-market sale of 8,929 common shares with updated direct ownership of 37,377 shares afterward.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/11/2026 - 06:18 PM Accepted by SEC EDGAR 08/11/2026 - 06:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Voigtlander Christian B.

(Last) (First) (Middle)

951 CALLE AMANECER

(Street)

SAN CLEMENTE CALIFORNIA 92673

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ICU MEDICAL INC/DE [ ICUI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2026		S		8,929	D	$182.9325(1)	37,377	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $182.85 to $183.03, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

	By: Paula Darbyshire, Attorney-in-Fact For: Christian Voigtlander	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)